title: Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538).
authors.affiliation: Department of Biotransformation, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
authors.forename: G N
authors.initials: GN
authors.lastname: Kumar
authors.forename: B
authors.initials: B
authors.lastname: Grabowski
authors.forename: R
authors.initials: R
authors.lastname: Lee
authors.forename: J F
authors.initials: JF
authors.lastname: Denissen
mesh_terms: D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004790:Enzyme Induction; D004997:Ethinyl Estradiol / Q000378:metabolism; D005260:Female; D014453:Glucuronosyltransferase / Q000096:biosynthesis*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism*; D009929:Organ Size; D051381:Rats; D017207:Rats, Sprague-Dawley; D019438:Ritonavir / Q000494:pharmacology*
chemical_list: D017320:HIV Protease Inhibitors; D004997:Ethinyl Estradiol; D003577:Cytochrome P-450 Enzyme System; D014453:Glucuronosyltransferase; D019438:Ritonavir